Alpha Cognition Inc.
Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.
Alpha Cognition Inc. (ACOG)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2024-1103 – Consolidation - Alpha Cognition Inc. (ACOG)
le 1 novembre/November 2024
Alpha Cognition Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 6,034,221 common shares.
The name and symbol will not change.
